Comparison of rh-PDGF and Enamel Matrix Derivatives with Bone Allograft to Treat Intra-bony Periodontal Defects

What this Trial Is About

This research focuses on treating intra-bony defects caused by periodontal disease, which can lead to changes in bone structure around teeth. The study evaluates and compares two treatments to improve bone regeneration and periodontal health recombinant human platelet derived growth factor rh-PDGF combined with bone allograft versus enamel matrix derivatives EMD combined with bone allograft. The goal is to assess the effectiveness of these therapies in patients with persistent deep probing depths and intra-bony defects. Participants will be randomly assigned to one of two groups. One group will receive rh-PDGF GEM-21 with allogenic bone graft, and the other group will receive EMD with allograft. Both groups will undergo the same surgical procedure. The study includes follow-up visits at 6 and 12 months after treatment to monitor progress and re-evaluate the results. During the study, patients will be assessed for clinical attachment changes and other periodontal health measures. Researchers will perform evaluations including probing depth measurements and radiographic imaging to observe bone gain and attachment improvements. The study aims to monitor treatment outcomes over a 12-month period, with safety and effectiveness assessments at specified intervals.

Rh-PDGF vs EMD for Treatment of Intra-bony Defects